GO:0003831 beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003831 describes the enzymatic activity that transfers galactose from UDP-galactose to N-acetylglucosamine residues on glycopeptides, forming a beta-1,4 linkage [1, 2].
• This activity is a classic Golgi-resident glycosyltransferase function, often used as a marker for Golgi-enriched fractions.
• The activity increases during differentiation of embryonal carcinoma and neuronal cells, linking it to developmental processes [1, 5].
• Elevated beta-1,4-galactosyltransferase activity has been observed in human ovarian and parotid neoplasms, suggesting a role in cancer biology [6, 7].
• Multiple beta-1,4-galactosyltransferase genes exist, including a human cDNA with 37% identity to the classical enzyme, indicating molecular diversity.
• Studying GO:0003831 requires combining enzymatic assays, CRISPR-based gene editing, and glycoproteomics to dissect its cellular roles.
Description
GO:0003831, beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity, is a molecular function that catalyzes the transfer of galactose from UDP-galactose to N-acetylglucosamine residues on glycopeptides, forming a beta-1,4 linkage [1, 2]. This activity is a key step in the biosynthesis of complex N-linked glycans and is carried out by enzymes localized primarily in the Golgi apparatus. Researchers study this activity because it influences glycoprotein structure and function, which in turn affect cell signaling, differentiation, and tumorigenesis [1, 5, 6]. The enzyme activity was first characterized in the early 1980s and has since been linked to retinoic acid-induced differentiation of F9 embryonal carcinoma cells and to neuronal differentiation of PC12 cells. Molecular cloning of human cDNAs encoding beta-1,4-galactosyltransferases has revealed multiple related genes, expanding the known family beyond the classical enzyme. The activity is also elevated in human ovarian cancer and parotid neoplasms, highlighting its potential as a biomarker or therapeutic target [6, 7]. Understanding GO:0003831 at the molecular, cellular, and organismal levels is therefore essential for glycobiology, developmental biology, and oncology research.
beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity At A Glance
| GO ID | GO:0003831 |
|---|---|
| GO term | beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity |
| Ontology | molecular_function |
| Synonym | UDP-galactose:N-acetyl-beta-D-glucosaminylglycopeptide beta-1,4-galactosyltransferase activity; glycoprotein 4-beta-galactosyltransferase activity; GalT activity |
| Major function | Transfer of galactose from UDP-galactose to N-acetylglucosamine on glycopeptides, forming a beta-1,4 linkage |
| Reaction | UDP-galactose + N-acetyl-beta-D-glucosaminylglycopeptide = UDP + beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminylglycopeptide |
| Localization | Golgi apparatus (as indicated by Golgi-enriched fraction isolation) |
| Substrates | UDP-galactose (donor), N-acetyl-beta-D-glucosaminylglycopeptide (acceptor) |
| Products | UDP, beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminylglycopeptide |
What Is GO:0003831?
GO:0003831 is defined as the catalysis of the reaction: UDP-galactose + N-acetyl-beta-D-glucosaminylglycopeptide = UDP + beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminylglycopeptide. In simpler terms, it is an enzyme activity that attaches a galactose sugar to a specific sugar (N-acetylglucosamine) on a glycopeptide, using UDP-galactose as the donor. This modification is part of the process that builds complex carbohydrate chains on proteins.
Why Is beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity Important in Cell Biology?
GO:0003831 is important because it represents a fundamental glycosylation step that modifies cell surface and secreted proteins, thereby affecting cell-cell recognition, signaling, and differentiation [1, 5]. Alterations in this activity have been associated with cancer progression, as seen in ovarian and parotid neoplasms [6, 7]. The enzyme is also a marker of Golgi function and is used to study intracellular trafficking and differentiation. Understanding its regulation and substrates can inform the development of glycoprotein-based therapeutics and diagnostics.
• Plays a key role in N-glycan biosynthesis and glycoprotein maturation [1, 2].
• Increases during retinoic acid-induced differentiation of F9 embryonal carcinoma cells.
• Elevated during PC12 cell differentiation induced by forskolin and 2-chloroadenosine.
• Serum activity with synthetic acceptors is elevated in human ovarian cancer.
• Increased expression is associated with human parotid neoplasms.
• Used as a marker for Golgi apparatus enrichment in leukaemic cells.
• Contributes to the diversity of beta-1,4-galactosyltransferase family members, including a human cDNA with 37% identity to the classical enzyme.
• Provides a target for studying glycosylation-dependent disease mechanisms and potential therapies [6, 7].
• Enables research on glycopeptide remodeling and glycan engineering.
• Supports the development of assays for enzyme activity in clinical samples.
Molecular Mechanism of beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity
Substrate Recognition and Binding
In simple terms: The enzyme grabs UDP-galactose and a glycopeptide carrying N-acetylglucosamine.
The enzyme binds UDP-galactose as the donor substrate and N-acetyl-beta-D-glucosaminylglycopeptide as the acceptor. This specificity ensures that galactose is transferred to the correct sugar residue on glycopeptides [1, 2]. The activity can be measured using synthetic low molecular weight acceptors, as demonstrated in human ovarian cancer serum.
Catalytic Transfer and Linkage Formation
In simple terms: The enzyme attaches galactose to the sugar via a beta-1,4 linkage.
The catalytic mechanism involves the transfer of galactose from UDP-galactose to the 4-hydroxyl group of N-acetylglucosamine, forming a beta-1,4 glycosidic bond. This reaction releases UDP and produces beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminylglycopeptide. The enzyme is a classic glycosyltransferase and has been purified from human kidney as a UDP-galactose:glucosyl ceramide beta-1,4-galactosyltransferase, indicating related activities.
Enzyme Localization and Golgi Function
In simple terms: The enzyme works mainly in the Golgi apparatus, the cell's packaging center.
The activity is enriched in Golgi apparatus fractions isolated from leukaemic cells, confirming its subcellular localization. This localization is consistent with its role in processing glycoproteins as they transit through the secretory pathway. The enzyme is also expressed in COS-1 cells, where a murine beta-1,4-galactosyltransferase was characterized.
Regulation and Isoforms
In simple terms: Different versions of the enzyme exist, and their activity changes with cell state.
Multiple beta-1,4-galactosyltransferase genes have been identified, including a human cDNA encoding an enzyme with 37% identity to the classical mammalian UDP-Gal:GlcNAc beta-1,4-galactosyltransferase. Activity increases during differentiation of F9 embryonal carcinoma cells and PC12 cells, suggesting developmental regulation [1, 5]. The enzyme's activity can also be modulated in cancer, as seen in ovarian and parotid neoplasms [6, 7].
Key Genes Involved in GO:0003831 beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity
The following genes and proteins are directly implicated in beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity or have been used to study it.
| Gene | Major Role | Research Relevance |
|---|---|---|
| B4GALT1 | Classical beta-1,4-galactosyltransferase; transfers galactose to GlcNAc on glycoproteins | Model enzyme for GO:0003831; studied in differentiation and cancer [1, 2] |
| B4GALT2 | Beta-1,4-galactosyltransferase family member with 37% identity to B4GALT1 | Human cDNA cloning revealed diversity; potential distinct functions |
| B4GALT3 | Beta-1,4-galactosyltransferase family member | May contribute to glycoprotein galactosylation; less characterized |
| B4GALT4 | Beta-1,4-galactosyltransferase family member | Potential role in glycosphingolipid synthesis |
| B4GALT5 | Beta-1,4-galactosyltransferase family member | Involved in lactosylceramide synthesis; related activity |
| B4GALT6 | Beta-1,4-galactosyltransferase family member | May synthesize glycosphingolipids |
| B4GALT7 | Beta-1,4-galactosyltransferase involved in proteoglycan synthesis | Distinct from glycopeptide activity but shares mechanism |
| UDP-Gal | Donor substrate | Essential for enzymatic reaction; measured in assays |
| GlcNAc | Acceptor sugar on glycopeptides | Defines substrate specificity |
| Golgi apparatus | Subcellular organelle where enzyme resides | Marker for Golgi enrichment |
| F9 embryonal carcinoma cells | Cell model for differentiation | Activity increases with retinoic acid treatment |
| PC12 cells | Neuronal differentiation model | Activity increases with forskolin and 2-chloroadenosine |
| COS-1 cells | Expression system for murine enzyme | Characterization of beta-1,4-galactosyltransferase |
| Human kidney | Source for purification of related enzyme | Purification of UDP-Gal:glucosyl ceramide beta-1,4-galactosyltransferase |
| Ovarian cancer serum | Clinical sample with elevated activity | Potential biomarker |
| Parotid neoplasms | Tissue with increased enzyme expression | Associated with tumorigenesis |
| Leukaemic cells | Source for Golgi fraction isolation | Used to study enzyme localization |
How Is beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity Regulated?
The activity of beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase is regulated during cell differentiation and in disease states. Retinoic acid-induced differentiation of F9 embryonal carcinoma cells leads to increased cell-surface activity. Similarly, forskolin and 2-chloroadenosine induce differentiation of PC12 cells with a concomitant rise in enzyme activity. In cancer, serum activity with synthetic acceptors is elevated in ovarian cancer patients, and increased expression is associated with parotid neoplasms. The enzyme's Golgi localization is a key regulatory feature, as its access to substrates depends on vesicular trafficking. No specific transcription factors or signaling pathways have been definitively linked to its regulation in the provided literature.
beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| B4GALT1 | Ovarian cancer; elevated serum activity | Ovarian cancer cell lines with B4GALT1 knockout or overexpression |
| B4GALT1 | Parotid neoplasms; increased expression | Parotid tumor cell lines and xenografts |
| B4GALT1 | Differentiation of embryonal carcinoma | F9 cells treated with retinoic acid |
| B4GALT1 | Neuronal differentiation | PC12 cells treated with forskolin |
| B4GALT2 | Glycosylation diversity | COS-1 cells expressing human B4GALT2 |
Ovarian Cancer
Serum beta-(1->4)-galactosyltransferase activity with a synthetic low molecular weight acceptor is elevated in human ovarian cancer, suggesting its potential as a biomarker for this malignancy. The enzymatic activity may reflect altered glycosylation patterns that contribute to tumor progression.
Parotid Neoplasms
Increased expression of beta-1,4-galactosyltransferase is associated with human parotid neoplasms, indicating a role in salivary gland tumorigenesis. This upregulation may affect cell surface glycoproteins involved in proliferation and invasion.
Differentiation and Development
The activity increases during retinoic acid-induced differentiation of F9 embryonal carcinoma cells and during PC12 cell differentiation induced by forskolin and 2-chloroadenosine. These findings link the enzyme to developmental processes and suggest that dysregulation could contribute to developmental disorders.
From beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does B4GALT1 knockout reduce glycopeptide galactosylation? | B4GALT1 knockout cell lines (e.g., HEK293) generated by CRISPR |
| Does a point mutation in the catalytic domain abolish enzyme activity? | Point-mutation knock-in of B4GALT1 in cell lines |
| Can tagged B4GALT1 be used to track Golgi localization? | Knock-in of fluorescent or epitope tags at the endogenous locus |
| Does overexpression of B4GALT1 alter cell surface glycans? | Stable overexpression in cancer cell lines |
| Which genes regulate B4GALT1 expression during differentiation? | CRISPR library screening in F9 or PC12 cells |
| Does B4GALT1 activity correlate with ovarian cancer progression? | Patient-derived xenografts or organoids with modulated B4GALT1 |
How to Study the beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic assay with synthetic acceptor | Beta-1,4-galactosyltransferase activity | Serum biomarker studies in ovarian cancer |
| Mass spectrometry glycoproteomics | Galactosylated glycopeptide structures | Global glycosylation profiling [1, 2] |
| CRISPR knockout | Loss of gene function | Causal testing of B4GALT1 in cells |
| CRISPR point mutation | Effect of specific amino acid changes | Catalytic mechanism studies |
| CRISPR knock-in of tags | Protein localization and interactions | Golgi tracking |
| Overexpression | Gain of function | Glycan remodeling in cancer cells |
| Golgi fraction isolation | Subcellular localization | Enzyme enrichment |
| Differentiation induction | Activity changes during development | F9 and PC12 models [1, 5] |
Enzymatic Activity Assays
Beta-1,4-galactosyltransferase activity can be measured using synthetic acceptors and radiolabeled UDP-galactose, as demonstrated in serum from ovarian cancer patients. These assays quantify the transfer of galactose to glycopeptide acceptors and are useful for comparing activity across cell states.
Glycoproteomics and Mass Spectrometry
Mass spectrometry can identify and quantify beta-1,4-galactosylated glycopeptides, providing a global view of the enzyme's products. This approach complements activity assays and can reveal changes in glycosylation patterns in disease [1, 2].
CRISPR-Cas9 Gene Editing
Knockout, point mutation, and knock-in of B4GALT genes using CRISPR-Cas9 enable causal studies of GO:0003831. For example, knockout of B4GALT1 can abolish specific galactosylation events, while tagged knock-in allows localization studies [2, 4].
Cell Differentiation Models
F9 embryonal carcinoma cells treated with retinoic acid and PC12 cells treated with forskolin are established models to study differentiation-associated changes in enzyme activity [1, 5]. These models can be combined with CRISPR editing to test gene function.
How CRISPR Can Be Used to Study GO:0003831 beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity
Knockout
CRISPR knockout of B4GALT1 or related genes can eliminate beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity, allowing researchers to study its role in glycoprotein biosynthesis, cell differentiation, and cancer. For example, knockout in F9 or PC12 cells could test whether differentiation-induced activity increases are required for the differentiation process [1, 5].
Point Mutation
Introducing point mutations in the catalytic domain of B4GALT1 can dissect the enzymatic mechanism and identify residues critical for substrate binding or catalysis. Such mutants can be expressed in COS-1 cells, a system previously used to characterize murine beta-1,4-galactosyltransferase.
Knock-in
Knock-in of epitope tags or fluorescent proteins at the endogenous B4GALT1 locus enables real-time tracking of the enzyme's Golgi localization and trafficking. This approach can validate findings from Golgi-enriched fraction studies.
Overexpression
Overexpression of B4GALT1 or other family members can increase beta-1,4-galactosylation of glycoproteins, mimicking the elevated activity seen in ovarian and parotid neoplasms [6, 7]. This can help identify downstream effects on cell signaling and tumorigenesis.
How EDITGENE Supports beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity Research
Researchers studying beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in glycosylation, differentiation, or cancer. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation of genes like B4GALT1 and its family members.
Contact EDITGENE today to design your custom CRISPR model for beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity research.
Frequently Asked Questions About beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity
What is beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity?
It is an enzyme activity (GO:0003831) that transfers galactose from UDP-galactose to N-acetylglucosamine on glycopeptides, forming a beta-1,4 linkage [1, 2].
What genes are involved in beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity?
The classical gene is B4GALT1, but other family members like B4GALT2 through B4GALT7 also encode related enzymes.
What is the reaction catalyzed by GO:0003831?
UDP-galactose + N-acetyl-beta-D-glucosaminylglycopeptide = UDP + beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminylglycopeptide.
Where does beta-1,4-galactosyltransferase activity occur in the cell?
It is primarily localized in the Golgi apparatus, as shown by Golgi-enriched fraction isolation from leukaemic cells.
How is beta-1,4-galactosyltransferase activity measured?
It can be measured using synthetic acceptors and radiolabeled UDP-galactose, as done in serum from ovarian cancer patients.
Is beta-1,4-galactosyltransferase activity linked to cancer?
Yes, elevated activity has been observed in human ovarian cancer and parotid neoplasms [6, 7].
Does beta-1,4-galactosyltransferase activity change during differentiation?
Yes, it increases during retinoic acid-induced differentiation of F9 embryonal carcinoma cells and during PC12 cell differentiation [1, 5].
What are the synonyms for GO:0003831?
Synonyms include UDP-galactose:N-acetyl-beta-D-glucosaminylglycopeptide beta-1,4-galactosyltransferase activity, glycoprotein 4-beta-galactosyltransferase activity, and GalT activity.
Can CRISPR be used to study beta-1,4-galactosyltransferase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable functional studies of B4GALT genes [2, 4].
What diseases are associated with beta-1,4-galactosyltransferase activity?
Ovarian cancer and parotid neoplasms show elevated activity, and differentiation defects may be linked to altered activity [1, 5, 6, 7].
Conclusion
GO:0003831, beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity, is a fundamental glycosylation function with critical roles in glycoprotein biosynthesis, cell differentiation, and cancer. Its enzymatic mechanism, regulation, and disease associations have been elucidated through decades of research using biochemical assays, cell models, and molecular cloning [1, 2, 5, 6, 7]. Understanding this activity provides insights into glycobiology and offers potential biomarkers and therapeutic targets. EDITGENE's CRISPR services empower researchers to dissect the causal roles of B4GALT genes and accelerate discoveries in this field.
References
- 1. Nakhasi HL et al.. 1984. Increase in cell-surface N-acetylglucosaminide beta (1----4)galactosyltransferase activity with retinoic acid-induced differentiation of F9 embryonal carcinoma cells.. FEBS Lett 168(2):222-6 PMID: 6427003
- 2. Sato T et al.. 1998. Molecular cloning of a human cDNA encoding beta-1,4-galactosyltransferase with 37% identity to mammalian UDP-Gal:GlcNAc beta-1,4-galactosyltransferase.. Proc Natl Acad Sci U S A 95(2):472-7 PMID: 9435216
- 3. Chatterjee S et al.. 1992. Purification of uridine diphosphate-galactose:glucosyl ceramide, beta 1-4 galactosyltransferase from human kidney.. J Biol Chem 267(10):7148-53 PMID: 1551920
- 4. Nakazawa K et al.. 1991. Characterization of a murine beta 1-4 galactosyltransferase expressed in COS-1 cells.. Eur J Biochem 196(2):363-8 PMID: 1706663
- 5. Roth JA et al.. 1991. Increase in beta-1,4-galactosyltransferase activity during PC12 cell differentiation induced by forskolin and 2-chloroadenosine.. J Neurochem 57(2):708-13 PMID: 1649258
- 6. Madiyalakan R et al.. 1987. Serum beta-(1----4)-galactosyltransferase activity with synthetic low molecular weight acceptor in human ovarian cancer.. Eur J Cancer Clin Oncol 23(7):901-6 PMID: 3117561
- 7. Humphreys-Beher MG et al.. 1990. Increased expression of the enzyme beta 1-4-galactosyltransferase is associated with human parotid neoplasms.. Proc Soc Exp Biol Med 193(4):293-300 PMID: 2157218
- 8. Warley A et al.. 1976. Isolation of a Golgi-apparatus-enriched fraction from leukaemic cells.. Biochem J 156(2):245-51 PMID: 821478
